FDA Adds Two Behavioral Health Firms to TEMPO Pilot, Including an AI Voice Agent for Talk Therapy
核心洞察
The FDA has expanded its TEMPO pilot to four participants, adding two behavioral health companies, Limbic and SonderMind (搜索), alongside Cadence Solutions (搜索) and Dexcom (搜索).
Limbic's "Unpacked (搜索)" delivers cognitive behavioral therapy for depression (搜索) and anxiety (搜索) through an AI voice agent, overseen by a clinician, to Medicare beneficiaries.
The FDA states plainly that the effectiveness of these devices for their intended uses has not yet been evaluated, and participation relies on enforcement discretion rather than approval.
The Food and Drug Administration has expanded its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot to four participants, adding two behavioral health companies — Limbic and SonderMind (搜索) — to a program that previously focused on monitoring blood sugar and blood pressure. The move marks the point where the initiative moved from physiological tracking in cardio-kidney-metabolic care into mental health treatment, a category where outcomes are self-reported and the therapeutic relationship itself is part of the treatment.
The current participant list names four manufacturers: SonderMind (搜索), Limbic, Cadence Solutions (搜索), and Dexcom (搜索). Half of them now sit in behavioral health.
An AI Voice Agent for Structured Talk Therapy
London-based Limbic will offer an AI mental health service called Unpacked (搜索) as part of the program. The service provides cognitive behavioral therapy for people with anxiety (搜索) or depression (搜索) through telephone calls with an AI voice agent, overseen by a clinician. The device is intended for use within a structured outpatient behavioral health service model to deliver cognitive behavioral therapy to Medicare beneficiaries with clinically significant depression or anxiety.
Limbic CEO Ross Harper said in a statement that the service is intended to address the shortage of mental health professionals.
Denver-based SonderMind (搜索) plans to offer a smartphone application to help reduce anxiety (搜索) and depression (搜索) in adults, as an adjunct to therapy or medication. The device, called the SonderMind Adjunctive Care Application (搜索), is contraindicated for people experiencing suicidality, manic episodes, psychosis, and PTSD.
A Contraindication List Longer Than the Indication
The most revealing part of the FDA's entry for the AI voice therapy product is not what it treats but who it must not treat. Unpacked (搜索) is contraindicated for people with suicidal or homicidal ideation, moderate to severe dementia or severe cognitive impairment, any psychiatric disorder with distinct psychotic features, active severe self-harm without suicidal intent, complex disorders without psychotic features such as bipolar II disorder and personality disorders, substance use disorder as a primary condition or risk of dangerous intoxication or withdrawal, eating disorders of any severity, acute physical health instability, and pregnancy.
The device also excludes patients 81 and older with a frailty indication, those receiving hospice or palliative care, patients 66 and older entering long-term nursing home care during the intervention window, and people who do not speak or read English or who lack access to a telephone.
That list is a reasonable safety design, but it is also a description of conditions that commonly accompany depression (搜索) and anxiety (搜索) in older adults — the population the Medicare model serves. Screening people into and out of the device correctly becomes a clinical task of its own.
Enforcement Discretion Is Not Approval
The regulatory mechanism deserves plain language. Under TEMPO, the FDA says it intends to exercise enforcement discretion for certain requirements, such as premarket authorization and investigational device requirements, when a participating manufacturer's device is offered to or by ACCESS participants for the listed intended use.
Enforcement discretion means the agency is choosing not to enforce rules that would otherwise apply. It is not clearance, not approval, and not a finding that a device works. In exchange, manufacturers collect, monitor, and report real-world data relating to those intended uses.
The FDA states plainly on its own participant page that the effectiveness of these devices, for the intended uses under which they are participating, has not yet been evaluated by the agency. For patients and families, that sentence is the whole story.
The rationale is coherent: software changes faster than a fixed review process can track, and a device can be materially different by the time a review concludes. The trade is that patients become part of the evidence-generating process rather than the beneficiaries of evidence already generated.
Clinical Oversight and the Disclosure Gap
The FDA's description of the device includes real-time safety flagging, measurement-based care, and support for clinical oversight. The pilot is not describing an unsupervised chatbot.
However, a gap remains for households around disclosure. A Medicare beneficiary offered a digital therapy program through their care team has no obvious way to know that the underlying device is operating under enforcement discretion rather than authorization. Nothing in the public participant materials specifies what patients are told, or in what terms.
Anyone offered a digital health program through a Medicare care model can reasonably ask three questions: Is this device FDA-authorized for this use, or is it in a pilot? Which clinician is responsible for my care and how do I reach them? And what happens to the data collected about me?
A Broader Push for Oversight
Amid the pilot program, the FDA has also held discussions on digital health technologies for mental health, with patient groups calling for broader oversight in the use of generative artificial intelligence.
Both selected companies will be able to offer their devices through a new Medicare payment model — the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model run by the CMS Innovation Center — that rewards providers for improving patient outcomes. The program is designed to support the use of technology to manage chronic health conditions.
The FDA says it intends to update its participant table as additional manufacturers are selected. That table, rather than any company announcement, is the authoritative record of what is in the program. Patients in mental health treatment should not stop, change, or substitute care based on this article; the pilot's terms describe these tools as sitting alongside clinical care rather than replacing it.